All lobbying filings

THE NICKLES GROUP, LLC

Lobbying for AMGEN · Biotechnology.

Filing 3rd Quarter - Report

3rd Quarter (July 1 - Sep 30) 2025 · California · House · Senate · $60,000.00 income · posted Oct 20, 2025

Official filing document

Bills named in this filing 3

HR 1
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
HR 946
ORPHAN Cures Act
S 1862
ORPHAN Cures Act

Lobbying activity 4

Taxation/Internal Revenue Code

H.R. 1 (P.L. 119-21), One Big Beautiful Bill Act, as it relates to corporate taxes.

Health Issues

Issues related to pharmacy benefit management. Issues related to cardiovascular care. Issues related to drug pricing.

Monitored issues related to intellectual property.

Medicare/Medicaid

Monitored implementation of P.L. 117-169, the Inflation Reduction Act as it relates to drug pricing. Issues related to biosimilars. Monitored issues related to cardiovascular health. Issues related to pharmacy benefit management. Monitored issues related to dialysis services. H.R. 1 (P.L. 119-21), One Big Beautiful Bill Act, as it relates to pharmacy benefit management and drug pricing policies. H.R. 946 / S. 1862, ORPHAN Cures Act. Issues related to the Most Favored Nation drug pricing.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.